

PRESS RELEASE

Stockholm, 16 May 2016



2013 long-term incentive programme meets objectives and vests in full

[Swedish Orphan Biovitrum AB's](#) (publ) (Sobi™) Board of Directors today announced that the company's 2013 long-term incentive programme met the objectives set and will vest in full. The total number of shares awarded to Sobi employees enrolled in the 2013 programme is 909,939.

A summary of the terms and conditions of Sobi's 2013 long-term incentive program can be found on in [Sobi's Annual Report 2015](#).

About Sobi™

Sobi™ is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ Stockholm.

For more information please contact

Media relations

Oskar Bosson, Head of Communications

T: +46 70 410 71 80

oskar.bosson@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

jorgen.winroth@sobi.com